These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31282310)

  • 41. Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update.
    Winograd J; Venishetty N; Codelia-Anjum A; Bhojani N; Elterman D; Zorn KC; Te A; Chughtai B
    Expert Opin Emerg Drugs; 2024 Sep; 29(3):205-217. PubMed ID: 38841744
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Re: Twelve-Month Medication Persistence in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia.
    Kaplan SA
    J Urol; 2015 Oct; 194(4):1056. PubMed ID: 26382807
    [No Abstract]   [Full Text] [Related]  

  • 43. Severe prostate enlargement with severe lower urinary tract symptoms in poorly controlled acromegaly successfully treated with 5α-reductase inhibitors: A 15-year longitudinal case report.
    Chen YC; Chen HW; Chen MT; Huang CH; Li CC; Juan YS; Ke HL
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O218-O220. PubMed ID: 29405593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of Structural Equation Modeling to Demonstrate the Differential Impact of Storage and Voiding Lower Urinary Tract Symptoms on Symptom Bother and Quality of Life during Treatment for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
    McVary KT; Peterson A; Donatucci CF; Baygani S; Henneges C; Clouth J; Wong D; Oelke M
    J Urol; 2016 Sep; 196(3):824-30. PubMed ID: 27105760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia.
    Yokoyama O; Ozeki A; Suzuki N; Murakami M
    Int J Urol; 2018 Mar; 25(3):240-245. PubMed ID: 29094398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.
    Füllhase C; Chapple C; Cornu JN; De Nunzio C; Gratzke C; Kaplan SA; Marberger M; Montorsi F; Novara G; Oelke M; Porst H; Roehrborn C; Stief C; McVary KT
    Eur Urol; 2013 Aug; 64(2):228-43. PubMed ID: 23375241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.
    Zabkowski T; Saracyn M
    J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of Benign Prostatic Hyperplasia.
    Kim EH; Larson JA; Andriole GL
    Annu Rev Med; 2016; 67():137-51. PubMed ID: 26331999
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adherence to therapy for lower urinary tract symptoms: don't mistake association with causation!
    Penson DF
    Eur Urol; 2015 Sep; 68(3):426-7. PubMed ID: 25703576
    [No Abstract]   [Full Text] [Related]  

  • 50. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. Letter.
    Tutolo M; Briganti A; Salonia A; Montorsi F
    J Urol; 2023 Jul; 210(1):33-34. PubMed ID: 37053542
    [No Abstract]   [Full Text] [Related]  

  • 52. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. Reply.
    Lenfant L; Pinar U; Roupret M; Mozer P; Chartier-Kastler E; Seisen T
    J Urol; 2023 Jul; 210(1):34-35. PubMed ID: 37053541
    [No Abstract]   [Full Text] [Related]  

  • 53. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
    Alcaraz A; Carballido-Rodríguez J; Unda-Urzaiz M; Medina-López R; Ruiz-Cerdá JL; Rodríguez-Rubio F; García-Rojo D; Brenes-Bermúdez FJ; Cózar-Olmo JM; Baena-González V; Manasanch J
    Int Urol Nephrol; 2016 May; 48(5):645-56. PubMed ID: 26810324
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trends in the development of new drugs for treatment of benign prostatic hyperplasia.
    Kulig K; Malawska B
    Curr Med Chem; 2006; 13(28):3395-416. PubMed ID: 17168713
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.
    Ingimarsson JP; Isaksson HJ; Sigbjarnarson HP; Gudmundsson J; Geirsson G
    Scand J Urol; 2014 Feb; 48(1):73-8. PubMed ID: 23924152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk factors for failure of long-term dutasteride add-on treatment to alpha-adrenergic antagonist for patients with lower urinary tract symptoms and benign prostatic enlargement.
    Wada N; Abe N; Miyauchi K; Ishikawa M; Makino S; Kakizaki H
    Int Urol Nephrol; 2022 Jan; 54(1):31-36. PubMed ID: 34767140
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
    Yuan JQ; Yang ZY; Mao C
    Eur Urol; 2012 Aug; 62(2):e35; author reply e36-8. PubMed ID: 22656724
    [No Abstract]   [Full Text] [Related]  

  • 59. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L
    Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.